Congenia Overview
- Founded
-
2004
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Congenia General Information
Description
Developer of biopharmaceutical drugs designed to target the mitochondrial permeability transition pore.The company's drugs are focused on developing inhibitors to stop the mitochondrial permeability transition that can lead to cell death, enabling patients and medical practitioners to clinically validate the pathogenesis of several diseases and other indications.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Primary Office
- Via Privata Giovannino De Grassi, 11
- 20123 Milan
- Italy
+39 02 0000 0000
Congenia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 18-Jun-2021 | Completed | Out of Business | |||
| 1. Buyout/LBO | Completed | Startup |
Congenia Patents
Congenia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2349982-B1 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Active | 27-Oct-2008 | 0000000000 | |
| EP-2349982-A1 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Active | 27-Oct-2008 | 0000000000 | |
| EP-2179984-A1 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Inactive | 27-Oct-2008 | 0000000000 | 0 |
| ES-2552051-T3 | Acrylamide derivatives useful as inhibitors of mitochondrial permeability transition | Active | 27-Oct-2008 | 0000000000 | |
| JP-2015003921-A | Acrylamide derivatives useful as inhibitors of the mitochondrial permeability transition | Pending | 27-Oct-2008 | C07C235/38 |